Table 2.
Systemic therapies and oncological outcomes
| Case | Systemic therapy | Best response (time to progression) | Oncological outcomes | Time from diagnosis of malignant TGCT |
|---|---|---|---|---|
| 1 | Doxorubicin + ifosfamide Gemcitabine + docetaxel Sirolimus (rapamycin) Sorafenib Sunitinib alone Sunitinib + sirolimus |
SD (4 M) SD (3 M) N.A. (8 M) PD (mixed response) SD (15 M) PR (8 M) |
DOD | 72 M |
| 2 | Sorafenib | PD | DOD | 20 M |
| 3 | Imatinib Doxorubicin + ifosfamide mTOR inhibitor PI3K/MTOR inhibitor Liposomal doxorubicin Ifosfamide Gemcitabine + docetaxel |
PD PR (4 M) PD PD PD PD PR (5 M) |
DOD | 23 M |
| 4 | Doxorubicin + ifosfamide Nilotinib Gemcitabine + docetaxel |
SD (3 M) PD PD |
DOD | 9 M |
| 5 | Doxorubicin (+/− an investigational drug) Paclitaxel Gemcitabine + vinorelbine |
PR (6 M) PD PD |
DOD | 17 M |
| 6 | Doxorubicin + ifosfamide Imatinib Pazopanib |
N.A. PD (mixed response) Too short to evaluate(1 W) |
DOD | 25 M |
SD stable disease, N.A data not available, PD progressive disease, PR partial response, DOD dead of disease; and AWD alive with disease